A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01%, while the ...

Shares of Amgen and IBM are posting strong returns Monday morning, sending the Dow Jones Industrial Average into positive territory.

In the case filed by Amgen last year, U.S. District Court Judge Nina Wang ruled that a Colorado state board can proceed with plans to limit the costs for medications. This is the first court decision ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

American Century Companies Inc. gave Amgen a financial haircut, slashing its stake by 46.3% and cashing in $36.76 million.

Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...